For research use only. We do not sell to patients.

Doxifluridine

CAS No. : 3094-09-5

Biological Activity：Doxifluridine(Ro 21-9738; 5′-DFUR) is a thymidine phosphorylase activator for PC9-DPE2 cells with IC50 of 0.62 μM.
IC50 value: 0.62 μM(PC9-DPE2 cell).
Target: Nucleoside antimetabolite/analog
Doxifluridine is a fluoropyrimidine derivative and oral prodrug of the antineoplastic agent 5-fluorouracil (5-FU) with antitumor activity. Doxifluridine, designed to circumvent the rapid degradation of 5-FU by dihydropyrimidine dehydrogenase in the gut wall, is converted into 5-FU in the presence of pyrimidine nucleoside phosphorylase. 5-FU interferes with DNA synthesis and subsequent cell division by reducing normal thymidine production and interferes with RNA transcription by competing with uridine triphosphate for incorporation into the RNA strand.
in vitro: 5′-DFUR’s metabolic product(N3-Me-5′-dFUR) was found to be non-toxic in all the cell growth experiments performed. The absence of cytotoxicity could be explained by the observation that the metabolite was not recognized as a substrate by thymidine phosphorilase, the enzyme responsible for 5-fluorouracil (5-FU) release from doxifluridine, as ascertained by high-performance liquid chromatography/ultraviolet (HPLC-UV) analysis of the incubation mixture[1].
in vivo: Administration of 200 mg of Furtulon to 23 beagle dogs, the plasma concentrations of doxifluridine, 5-FU, and 5-FUrd were measured simultaneously, using LC-MS/MS. The parent-metabolite compartment model with first-order absorption and Michaelis-Menten kinetics described the pharmacokinetics of doxifluridine, 5-FU, and 5-FUrd. Michaelis-Menten kinetics sufficiently explained the generation and elimination processes of 5-FU and 5-FUrd[2].
Clinical trial: A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer was reported in 2009[3].

Research Area：Cancer

Targets：Nucleoside Antimetabolite/Analog

Related Screening Libraries:Drug Repurposing Compound Library Plus;FDA-Approved Drug Library Plus;FDA-Approved Drug Library Mini;Bioactive Compound Library Plus;Cell Cycle/DNA Damage Compound Library;FDA-Approved Drug Library;Anti-Cancer Compound Library;Anti-Aging Compound Library;Drug Repurposing Compound Library;Reprogramming Compound Library;Nucleotide Compound Library;Anti-COVID-19 Compound Library;NMPA-Approved Drug Library;FDA Approved & Pharmacopeial Drug Library;Anti-Lung Cancer Compound Library;Drug-Induced Liver Injury (DILI) Compound Library;Anti-Blood Cancer Compound Library;Anti-Cancer Metabolism Compound Library;FDA-Approved Anticancer Drug Library;Human Metabolite Library;

Related Small Molecules:m7GpppCpG;7-TFA-ap-7-Deaza-dA;m7GpppUmpG;DMT-2′-F-Bz-dA;Cytidine-d1;Dmt-2′-f-dc(ac) amidite;Uridine 13C-1;8-Azaguanine;7-TFA-ap-7-Deaza-ddA;Vidarabine;2′-F-Bz-dC Phosphoramidite;2′-OMe-A(Bz) Phosphoramidite;5′-O-DMT-N6-Me-2′-dA;Enocitabine;3′-Azido-3′-deoxy-beta-L-uridine

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

About Us:

• MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use；
• Structurally and synthetically diverse biologically active compounds；
•  roduct quality is the key to our success and we take pride in offering only the highest-grade products.；
• We provide HNMR, LC-MS, HPLC, stability testing and activity assays of our products to clients.；
• Product identity, quality, purity and activity are assured by our robust quality control programs and procedures.；

Structurally and synthetically diverse biologically active compounds；

• Customized order volume ranging from milligrams to kilograms scale；

We provide customer-oriented services. To explore more, please contact us at [email protected]. Our team will gladly assist you.